Completed OBSERVATIONAL NCT03045419

Added Value of Gadoxetic Acid-enhanced Liver MRI

Added Value of Gadoxetic Acid-enhanced Liver Magnetic Resonance Imaging for Diagnosis of Small (10-19 mm) or Atypical Hepatic Nodules at Contrast-enhanced Computed Tomography: A Prospective Study

Sponsor: Bayer

Conditions Diagnosis Hcc

Interventions gadoxetic acid-enhanced liver MRI

Updated 6 times since 2017 Last updated: Feb 3, 2017 Started: Dec 29, 2009 Primary completion: Nov 24, 2013 Completion: Dec 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03045419, this observational or N/A phase trial focuses on Diagnosis and Hcc and remains completed. Sponsored by Bayer, it has been updated 6 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed
Sep 2024 — Sep 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Apr 2018 — Jan 2021 [monthly]

Completed

Phase: NA → None

▶ Show 1 earlier version

Feb 2017 — Apr 2018 [monthly]

Completed NA

First recorded

Dec 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bayer
Seoul National University Hospital

Data source: Seoul National University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea